Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
179.71
+1.98 (1.11%)
At close: Sep 26, 2025, 4:00 PM EDT
179.94
+0.23 (0.13%)
After-hours: Sep 26, 2025, 7:58 PM EDT
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $23.74B in the quarter ending June 29, 2025, with 5.77% growth. This brings the company's revenue in the last twelve months to $90.63B, up 4.68% year-over-year. In the year 2024, Johnson & Johnson had annual revenue of $88.82B with 4.30% growth.
Revenue (ttm)
$90.63B
Revenue Growth
+4.68%
P/S Ratio
4.77
Revenue / Employee
$656,242
Employees
138,100
Market Cap
432.80B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 29, 2019 | Pro | Pro | Pro |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
| Jan 3, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
| Thermo Fisher Scientific | 43.21B |
JNJ News
- 3 days ago - Johnson & Johnson (JNJ) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 4 days ago - J&J to withdraw acid reflux device from non-US markets, Bloomberg News reports - Reuters
- 5 days ago - These are the top 22 stocks pushing the S&P 500 into record territory — and it's not all Big Tech - Market Watch
- 8 days ago - TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen - PRNewsWire
- 8 days ago - TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma - PRNewsWire
- 8 days ago - Johnson & Johnson receives positive CHMP opinion of nipocalimab to treat a broad population of antibody-positive patients living with generalised myasthenia gravis (gMG) - GlobeNewsWire
- 10 days ago - J&J's experimental psoriasis drug shows promise against Bristol's treatment - Reuters
- 10 days ago - Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis - PRNewsWire